We continue to monitor the monkeypox outbreak in Washington and the United States. Report possible monkeypox cases immediately upon suspicion, as Washington State Department of Health (DOH) requires. Call . We will help you complete an intake form and review exposure guidelines to evaluate close contacts. Monkeypox is rare and not often seen in the United States. It can cause a rash … 07/26/22 Health Advisory: Monkeypox Update
Requested actions Washington currently has 16 reported cases of monkeypox, mostly in King County. Early cases were linked to travel but Public Health Seattle–King County announced last week the virus is likely spreading locally. Monkeypox is rare and not often seen in the United States. It can cause a rash that looks like bumps, blisters … 07/14/22 Health Advisory: Updated Monkeypox Guidance
Requested actions Immediately report suspected monkeypox cases to Yakima County Health District. Call the reporting line at 800-535-5016 ext. 541. Consider submitting a suspect monkeypox intake form to help us determine whether to test for monkeypox. Be aware, recent confirmed cases of monkeypox in the United States differ from the classic monkeypox presentation of previous … 06/24/22 Health Advisory: Updated Monkeypox Guidance
A person in Colorado tested positive for avian influenza A(H5N1) virus (H5 bird flu), Colorado Department of Public Health and Environment reported April 28, 2022. Centers for Disease Control and Prevention (CDC) confirmed it is the first U.S. case of H5 bird flu. The person was involved in the culling of poultry with presumptive H5 … 05/05/22 Health Advisory: Colorado person first U.S. case of H5 bird flu
Requested actions Be aware, on April 25, 2022, Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) advisory about the availability and use of recommended COVID-19 therapies. It also advised against using unproven treatments that have known or potential harm. Follow National Institutes of Health (NIH) COVID-19 treatment guidelines and use … 04/27/22 Health Advisory: CDC Treatment Updates and ACIP discusses eligibility for second booster dose of COVID-19 vaccine
Requested actions Be aware, on April 25, 2022, Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) advisory about the availability and use of recommended COVID-19 therapies. It also advised against using unproven treatments that have known or potential harm. Follow National Institutes of Health (NIH) COVID-19 treatment guidelines and use … 04/27/22 Health Advisory: CDC Treatment Updates and ACIP discusses second COVID-19 booster dose eligibility
Requested actions Be aware, on March 29, 2022, Food and Drug Administration (FDA) amended its emergency use authorization (EUA) for Moderna COVID-19 booster dose vaccine. A new multi-dose vial is now available. It has a dark blue cap and a label with a purple border. Doses from this vial are 0.5 mL. Multi-dose vials are … 04/08/22 Health Advisory: COVID-19 Information for Providers
Requested actions Be aware, Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup endorsed Food and Drug Administration’s (FDA’s) emergency use authorization (EUA) of a second booster dose of Pfizer or Moderna COVID-19 vaccines for specific groups. The EUA allows: A second booster dose of Pfizer COVID-19 vaccine at least … 03/30/22 Health Advisory: CDC endorses second booster dose of mRNA COVID-19 vaccine for certain groups
Requested actions Be aware, on March 4, Washington State Department of Health (DOH) discontinued ordering Johnson & Johnson COVID-19 vaccine because inventory is very low at Centers for Disease Control and Prevention (CDC) in Washington Immunization Information System (IIS). We encourage providers to post and look for available doses on IIS vaccine advertisement page. Email … 03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings
Requested actions Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a … 02/25/22 Health Advisory: COVID-19 Updates for Providers
